Stocktwits on MSN

Lexeo Therapeutics Stock Rallies On Discussions With FDA To Expedite Friedreich’s Ataxia Drug Approval Process

Lexeo Therapeutics (LXEO) announced on Tuesday that the company is considering a smaller pivotal study for LX2006 in the ...

Belhaven Biopharma Initiates a Pivotal Biocomparability Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Nasdepi(R) vs. Epinephrine Intr…

Application Receives FDA Authorization to Proceed RALEIGH, NORTH CAROLINA / ACCESS Newswire / October 8, 2025 / Belhaven ...
PharmExec

How Cell and Gene Therapy Developers Can Reduce Risk of FDA Complete Response Letters With Proactive CMC Strategies

How cell and gene therapy developers can lessen the chances of receiving FDA complete response letters through the use of ...
BioSpace

New Confirmatory Study Hints at ‘Alignment’ Between Applied Therapeutics, FDA for Rare Disease Drug

Applied Therapeutics has yet to confirm whether the study, posted on Clinicaltrials.gov on Thursday, means it has indeed ...
Asianet Newsable on MSN

Lexeo Therapeutics Stock Hits 11-Month High On Bullish Analyst Calls For Friedreich’s Ataxia Gene Therapy — Retail Traders Join In

Analysts raised price targets and boosted approval odds after the FDA signaled support for a faster review process, citing ...
Pharmabiz

Lexeo Therapeutics reports progress in US FDA discussions for accelerated approval pathway for LX2006 in Friedreich ataxia cardiomyopathy

Lexeo Therapeutics reports progress in US FDA discussions for accelerated approval pathway for LX2006 in Friedreich ataxia cardiomyopathy: New York Saturday, October 11, 2025, 16: ...